Emtriva
Emtriva is an originator product from Gilead Sciences Switzerland Sàrl and is listed on the FOPH Specialities List. Swiss mandatory health insurance therefore reimburses it within the authorised indication. The public price ranges from CHF 213.85 to CHF 213.85 depending on the pack; the patient co-payment is 10 per cent plus the deductible.
Core data
- Authorisation holder
- Gilead Sciences Switzerland Sàrl
- ATC code
- J05AF09
- IT group
- 08.03 Mittel gegen Viren
- Active substances
- Emtricitabinum
- Preparation type
- Originator product
- On the SL since
- 01/12/2004
- Last price change
- 01/12/2025
- Co-payment
- 10%
Prices per pack
The ex-factory price is the authorisation holder's price; the public price adds the distribution share and VAT. Both are FOPH maximum prices: nothing above them may be charged.
| Dosage form | Pack size | Ex-factory price | Public price | Valid from | Cat. | GTIN |
|---|---|---|---|---|---|---|
| Kaps 200 mg | 30 Stk | CHF 181.54 | CHF 213.85 | 01/12/2004 | A | 7680568800033 |
Limitation
No limitation is recorded on the SL for this preparation.
FAQ
Is Emtriva covered by Swiss health insurance?
Yes. Emtriva is on the FOPH Specialities List, so Swiss mandatory health insurance reimburses it within the authorised indication. You still pay the deductible and a co-payment of 10 per cent.
What does Emtriva cost in Switzerland?
The public price is the maximum price set by the FOPH and for Emtriva ranges from CHF 213.85 to CHF 213.85 per pack. The ex-factory price ranges from CHF 181.54 to CHF 181.54. Pharmacies may not charge more, but may charge less.
Market access
Do you need your product on the Specialities List?
Questions about SL listing, prices or limitations? Contact Swiss Reimbursement.
- Independent directory
- Official FOPH data
- Website in eight languages